For Clinical Trials
The DHR Health Institute for Research and Development has clinical trials that are actively recruiting qualified patients. For more detailed information about inclusion and exclusion criteria please contact the Research Department at 956-362-2390.
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults (PREVENTABLE)
Cladribine Tablets: Observational Evaluation Of Effectiveness And Patient-Reported Outcomes (Pros) In Suboptimally Controlled Patients Previously Taking Oral Or Infusion Disease Modifying Drugs (Dmds) For Relapsing Forms Of Multiple Sclerosis (RMS) (MASTER-2)
A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study, Comparing The Efficacy And Safety Of LOU064 100 Mg BID Versus Teriflunomide 14 Mg QD In Participants With RMS, Followed By Extended Treatment With Open-Label LOU064
A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation
"Single-blind Lead-in, to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients with Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)"
"A Randomized, Double-blind, Placebo-controlled, Phase 2b study to Evaluate Safety and Efficacy of DUR-928 in Subjects with Alcoholic Hepatitis"
An Observational Follow-Up Study for Subjects who have Participated in Aldafermin NASH Study 18-0108 (ALPINE 2/3)
An Adaptive Two-Part Phase 2, Multi-Center, Randomized, Double Blind, Placebo-Controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224 Administered Once Monthly in Adult Subjects with Confirmed Non-Alcoholic Steatohepatitis
Merck Sharp and Dohme LLC, (a subsidiary of Merck & Co. Inc., Rahway, New Jersey, USA)/ A phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis.
Ascend-nash: A Phase 2B, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate The Efficacy and Safety of CRV431 In Adult Subjects With Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis
A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Remetirom on Liver-Related OUtcomes in Patients with Well-compensated (Child-Pugh A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis (MAESTRO-NASH OUTCOMES)
SPRUCE 204: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects with Classic Congenital Adrenal Hyperplasia
"INHALE: A 26-week Primary Treatment Phase, with 26-week Extension, Open-label, Randomized Clinical Trial Evaluating the Efficacy and Safety of Afrezza® Versus Rapid-acting Insulin Analog Injections, Both in Combination with a Basal Insulin, in Pediatric Subjects with Type 1 or Type 2 Diabetes Mellitus"
ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications
"I-SPY COVID Trial: An Adaptive Platform Trial to Reduce Mortaility and Ventilator Requirements for Critically Ill Patients
"ACTIV-4A ACUTE: A Multicenter, Adaptive, Randomized, Open Label Controlled Platform Trial of the Safety and Efficacy of Antithrombotic and Additional Strategies in Hospitalized Adults with COVID-19"
BIOSPECIMEN COLLECTION TRIALS
Newly Diagnosed Colorectal Cancer
Fresh tissue- Various Cancer Types
Whole Blood- Various Cancer Types
Sample Collection Study for the CellMax Life Circulating Tumor Cell and Circulating Tumor DNA Platforms for the Early Detection of Colorectal Cancer and Adenomas
Liquid vs Tissue Biopsy Concordance in Samples of 1st Suspected BCa Recurrence & Metastasis
Solid Tumors- Whole Blood
Irritable Bowel Disease - Whole Blood
CRC Adenocarcinoma - Whole Blood
Healthy Control, CRC, AA - Whole Blood
Various Cancers - Whole Blood
LPC-001: Cancer Malignancy Longitudinal Project
ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation
Tracking treatment pathways in adult patients with hyperkalemia (TRACK): A prospective, non-interventional, longitudinal study of the treatment journey of adult patients with hyperkalemia
Enabling a Paradigm Shift: A Preference-Tolerant RCT of Personalized vs. Annual Screening for Breast Cancer (Wisdom Study)
Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
A Phase II study of Atezolizumab and Bevacizumab in Child-Pugh B7 Hepatocellular Carcinoma (The AB7 Trial)
"A Randomized Phase II Study of Intrabucally Administered Electromagnetic Fields versus Placebo for Patients with Child-Pugh A or B Advanced Hepatocellular Carcinoma"
Palivizumab-Controlled Evaluation of Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV Disease
SEQaBOO: SEQuencing a Baby for an Optimal Outcome
"A 26-Week, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Trial with a 26-Week Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and 10 mg, and Saxagliptin 2.5 and 5 mg in Pediatric Patients with Type 2 Diabetes Mellitus Who Are Between 10 and Below 18 Years of Age"
DHR Health proudly meets the federal definition of a “physician-owned hospital” (42 CFR § 489.3). As required by law, a list of the hospital’s physician owners and investors is available at www.dhrhealth.com. DHR, Ltd. and its affiliated entities comply with applicable Federal civil rights laws and do not discriminate on the basis of race, color, national origin, age, disability, or sex.